KRAS Mutation Prediction for Cdc7 Inhibitor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pancreatic cancer lack predictive markers to determine patient response to Cdc7 kinase inhibitors, making it difficult to identify effective therapies and potentially leading to unnecessary treatments.
Innovation Solution
The use of KRAS gene mutation status as a predictive marker to determine the likelihood of patient response to the Cdc7 kinase inhibitor 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one, with additional consideration of Tp53 and p16Ink4 gene mutations, to tailor treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Cdc7 kinase inhibitor treatment is administered to all pancreatic cancer patients, then some patients may benefit from the therapy, but many patients will undergo ineffective treatments leading to wasted resources and unnecessary side effects
Solution Approach 1:
The patent performs preliminary genetic testing for KRAS mutations before initiating Cdc7 kinase inhibitor treatment. This advance detection allows clinicians to pre-identify patients who are likely to respond to the therapy, ensuring that treatment is only administered to appropriate candidates and avoiding waste of resources on patients who would not benefit.
2Measurement precision
If genetic testing for KRAS mutations is performed to identify responsive patients, then treatment precision is improved, but additional testing time and cost are incurred
Solution Approach 1:
The patent utilizes existing genetic testing infrastructure and methodologies to detect KRAS mutations. By leveraging established testing platforms that are already integrated into clinical workflows, the additional time and cost burden is minimized while still achieving high prediction accuracy for treatment response.
Data Source
AI summary
The present invention relates to a method of predicting the likelihood that a patient will respond therapeutically to a pancreatic cancer treatment comprising the administration of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one (Compound 1) and/or tautomers thereof or a pharmaceutically acceptable salt or hydrate thereof, comprising the steps of: STEP (1): determining a KRAS gene mutation status of a sample from a patient, and STEP (2): predicting an increased likelihood that the patient will respond therapeutically to the pancreatic cancer treatment if the patient has the presence of KRAS gene mutation(s), and to methods of treating pancreatic cancer.